Effects of Probiotic Supplementation on Stress and Anxiety in Students (PROfoS)

November 16, 2026 updated by: Nordic Biotic Sp. z o.o.

The Efficacy of Probiotic Supplementation in Reducing Stress and Anxiety: A Randomized, Placebo-Controlled Study in Healthy Students During the Examination Period

This randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of 8-week supplementation with a probiotic combination of Lactobacillus plantarum LP140 and Bifidobacterium breve BB010 (total daily dose of 1 × 10¹⁰ CFU) compared with matching placebo in healthy university students during the examination period. The study aimed to determine whether probiotic supplementation reduced perceived stress and anxiety and improved related psychological parameters.

The primary outcomes were changes in Perceived Stress Scale (PSS-10) scores from baseline to weeks 5 and 8, compared with placebo. Secondary outcomes included changes in Depression Anxiety Stress Scales-21 (DASS-21) subscales (Stress, Anxiety, and Depression), State-Trait Anxiety Inventory - State scale (STAI-S), Sense of Coherence Scale (SOC-29), Pittsburgh Sleep Quality Index (PSQI), self-reported gastrointestinal symptoms assessed using a Likert scale, and the incidence of adverse events during the 8-week intervention.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The gut-brain axis enables bidirectional communication between the gastrointestinal tract and the central nervous system. Emerging evidence suggests that selected probiotic strains (psychobiotics) may modulate stress responses and emotional regulation. University examination periods constitute a predictable model of transient psychological stress in otherwise healthy individuals.

This randomized, double-blind, placebo-controlled study investigated whether daily supplementation with a probiotic combination of Lactobacillus plantarum LP140 and Bifidobacterium breve BB010 reduced perceived stress and improved psychological parameters in healthy students exposed to exam-related stress. A total of 242 male and female students aged 18-40 years were randomized at the Medical University of Lublin, Poland. The final inclusion criteria required at least moderate stress (Depression Anxiety Stress Scales-21 [DASS-21] Stress score ≥10) and a DASS-21 Depression score ≤9. A preliminary screening involving 100 students indicated that the originally proposed DASS-21 Anxiety criterion (score 6-13) was overly restrictive, substantially reducing the number of eligible students. Consequently, this criterion was removed before the commencement of formal recruitment and randomization. All participants enrolled in the randomized trial were assessed according to the same revised eligibility criteria.

After providing electronic informed consent and confirming eligibility through online screening, participants were randomized in a 1:1 ratio to receive either a probiotic formulation containing Lactobacillus plantarum LP140 and Bifidobacterium breve BB010 (total daily dose of 1 × 10¹⁰ colony-forming units) or a matching placebo. Written informed consent was obtained at the baseline visit before dispensing the study product.

The investigational product and placebo were identical in appearance and administered orally once daily (two capsules) for 8 weeks. Randomization was computer-generated, and both participants and investigators remained blinded to treatment allocation throughout the study. The intervention was scheduled to begin approximately six weeks before the first academic examination.

Study assessments were conducted at baseline, at week 5 (approximately one week before the first examination), and at week 8 (before a subsequent examination, with a ±3-day assessment window). Psychological and functional parameters were collected using validated self-report instruments administered electronically, with selected assessments performed during on-site visits. Participants were asked to maintain their usual diet, physical activity, and caffeine intake during the study period. Safety and tolerability were monitored throughout the intervention, and adverse events were recorded using an electronic reporting system with daily reminders.

The study was originally powered to detect clinically meaningful differences between groups in perceived stress levels. Statistical analyses included covariance-based models adjusted for baseline values and relevant covariates, together with longitudinal analyses. All participant data were coded to ensure confidentiality and handled in accordance with applicable data protection regulations.

Study Type

Interventional

Enrollment (Actual)

242

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Lublin, Poland
        • University of Lublin, Faculty of Health Sciences

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Male or female students aged 18-40 years
  • At least moderate stress (DASS-21 Stress score ≥10)
  • No clinical depression (DASS-21 Depression score ≤9)
  • Willingness to maintain usual diet, physical activity, and intake of caffeinated beverages during the study
  • Written informed consent

Exclusion Criteria:

  • Irritable bowel syndrome (Rome IV criteria) or any chronic intestinal disease (including celiac disease)
  • Known food allergies, immunodeficiency disorders, or immunosuppressive treatment
  • Antibiotic use within 4 weeks prior to screening
  • Any psychiatric illness within the past 5 years
  • Any malignant disease or autoimmune or allergic diseases (e.g., atopic dermatitis, asthma)
  • Use of systemic psychotropic medications or steroids; use of topical corticosteroid creams within 4 weeks prior to screening
  • Pregnancy, breastfeeding, or plans to become pregnant during the study
  • Probiotic or prebiotic consumption or planned dietary changes within 4 weeks prior to screening
  • Heavy caffeine consumption (>4 cups of 300 mL coffee per day)
  • Drug or alcohol addiction or regular use of recreational drugs
  • Smoking more than 10 cigarettes per day

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Probiotic

Two capsules containing Lactobacillus plantarum LP140 and Bifidobacterium breve BB010 will be administered orally once daily (total daily dose of 1 × 10¹⁰ colony-forming units) for 8 weeks.

Lactobacillus plantarum LP140 and Bifidobacterium breve BB010

Placebo Comparator: Placebo

Maltodextrin will be used as a placebo. The placebo capsules will be identical in appearance to the probiotic capsules and will be administered orally once daily (two capsules) for 8 weeks.

Maltodextrin

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in perceived stress score
Time Frame: Change in total perceived stress score from baseline to week 5 and to week 8 (±3 days) compared to placebo

Perceived stress will be assessed using the 10-Item Perceived Stress Scale (PSS-10), a validated questionnaire measuring the degree to which situations in one's life are appraised as stressful. The total score ranges from 0 to 40, with higher scores indicating higher perceived stress levels (worse outcome). Changes in the total score from baseline will be analyzed to evaluate the effect of probiotic supplementation.

Change in total perceived stress score from baseline to week 5 and to week 8 (±3 days) compared to placebo

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in stress, anxiety and depression scores
Time Frame: Change in DASS-21 Stress, Anxiety, and Depression subscale scores from baseline to week 5 and week 8 (±3 days) compared to placebo.

Stress, anxiety, and depression will be assessed using the Depression Anxiety Stress Scales - 21 Items (DASS-21). The DASS-21 consists of three subscales (Depression, Anxiety, and Stress), each including 7 items. Scores for each subscale range from 0 to 42 after standard score multiplication, with higher scores indicating greater symptom severity (worse outcome). Changes in the Stress, Anxiety, and Depression subscale scores from baseline will be analyzed to evaluate the effect of probiotic supplementation.

Change in DASS-21 Stress, Anxiety, and Depression subscale scores from baseline to week 5 and week 8 (±3 days) compared to placebo.
Change in sleep quality score
Time Frame: Change in Pittsburgh Sleep Quality Index (PSQI) global score from baseline to week 5 and week 8 (±3 days) compared to placebo.

Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI), a validated questionnaire measuring sleep quality over the previous month. The global PSQI score ranges from 0 to 21, with higher scores indicating poorer sleep quality (worse outcome). Changes in the PSQI global score from baseline will be analyzed to evaluate the effect of probiotic supplementation.

Change in Pittsburgh Sleep Quality Index (PSQI) global score from baseline to week 5 and week 8 (±3 days) compared to placebo.
Change in severity of gastro-intestinal symptoms
Time Frame: Change from baseline in gastro-intestinal severity score at Week 5 and Week 8 compared to placebo

The severitty of gastro-intestinal symptoms will be assessed with the use of 4-point Likert scale (0 - no symptom, 1 - weak, 2 - moderate, 4 - severe). The following symptoms will be assessed: abdominal pain, flatulence, nausea.

Change from baseline in gastro-intestinal severity score at Week 5 and Week 8 compared to placebo
Incidence of treatment-emergent adverse events (Safety and Tolerability)
Time Frame: From baseline through the 8-week intervention period.

Safety and tolerability will be assessed by monitoring the incidence of adverse events throughout the study. Adverse events will be self-reported by participants using an electronic reporting platform, which provides daily reminders for study product intake and allows participants to record any symptoms or adverse events experienced during the study period.

From baseline through the 8-week intervention period.
Change in sense of coherence score
Time Frame: Change in Sense of Coherence Scale - 29 Items (SOC-29) total score from baseline to week 8 (±3 days) compared to placebo.

Sense of coherence will be assessed using the Sense of Coherence Scale - 29 Items (SOC-29), a validated questionnaire measuring psychological resilience and the ability to cope with stress. The total score ranges from 29 to 203, with higher scores indicating a stronger sense of coherence (better outcome). Changes in the SOC-29 total score from baseline will be analyzed to evaluate the effect of probiotic supplementation.

Change in Sense of Coherence Scale - 29 Items (SOC-29) total score from baseline to week 8 (±3 days) compared to placebo.
Change in state anxiety score
Time Frame: Change in State-Trait Anxiety Inventory - State version (STAI-S) total score from baseline to week 8 compared to placebo.

State anxiety will be assessed using the State-Trait Anxiety Inventory - State version (STAI-S, also referred to as STAI X-1), a validated questionnaire measuring the current level of anxiety. The STAI-S total score ranges from 20 to 80, with higher scores indicating higher levels of anxiety (worse outcome). Changes in the STAI-S total score from baseline will be analyzed to evaluate the effect of probiotic supplementation.

Change in State-Trait Anxiety Inventory - State version (STAI-S) total score from baseline to week 8 compared to placebo.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Emilia Majsiak, PhD, Medical University of Lublin

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 23, 2026

Primary Completion (Actual)

July 1, 2026

Study Completion (Actual)

July 7, 2026

Study Registration Dates

First Submitted

March 10, 2026

First Submitted That Met QC Criteria

March 10, 2026

First Posted (Actual)

March 13, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • CT/NB/180/2025/PR-MS

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

No formal plan for sharing individual participant data has been established. The study data are retained by the Principal Investigator and are not publicly available due to participant confidentiality and data protection considerations.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.